Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

NCT06279130 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

133

Enrollment

OTHER

Sponsor class

Conditions

Resectable MMR-deficient Solid Tumors
Resectable MMR-proficient Solid Tumors

Interventions

DRUG: botensilimab
DRUG: balstilimab
DRUG: FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]